MedTrace Logo

Blood Biomarker of Alzheimer's Disease (AD)

NCT03340571 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2019-10-23

No results posted yet for this study

Summary

Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage where there are clinical manifestations. The identification and validation of high throughput biomarkers to measure disease progression (as well as identify pre-clinical disease onset) is critical to the development of disease-modifying or even preventative therapies. In this study, we are testing a blood biomarker for stratification of Alzheimer's disease patients and healthy volunteers. This study may lead to future blood tests that may help earlier diagnosis of Alzheimer's disease and detect the disease progression.

Conditions

  • Alzheimer Disease

Sponsors & Collaborators

Principal Investigators

  • Laurie Sanders, PhD · Assistant Professor

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-12
Primary Completion
2019-07-31
Completion
2019-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03340571 on ClinicalTrials.gov